La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Structure Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Structure Therapeutics..

Structure Therapeutics (NASDAQ:GPCR) Azioni, Catena delle Opzioni

STRUCTURE THERAPEUTICS INC

Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics Inc

You may be striving. You may be focused. You may have a solid job, a growing portfolio, a paid-off home—or maybe you're just getting started but doing all the right things. Saving. Investing. Staying disciplined.
But how do you <a href="https://www.benzinga.com/personal-finance/management/25/07/46521282/are-you-rich-or-just-comfortable-heres-the-net-worth-americans-think-you-need-for-both">know how you're really doing</a>?
Sure, wealth isn't a competition. But there are numbers for a reason. National surveys exist to help people gauge where they stand, and in terms of hard data, net worth percentile rankings are one of the clearest ways to find out.
So, let's talk about the top 2%—that narrow slice of households who've climbed near the top of the financial ladder. Where do they stand? How do they get there? And just how far—or close—might you be?
Don't Miss:
<ul class="wp-block-list">
<li>Be part of the breakthrough that could replace plastic as we know it—<a href="https://www.benzinga.com/money/timeplast-advertorial">invest in Timeplast before the July 31st deadline and help revolutionize a $1.3T industry.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">What It Takes To Be in the Top 2%</h2>
To land in the top 2% of U.S. households by net worth, most estimates place the threshold at around $5.5 million. This figure is based on 2022 data from the Federal Reserve's Survey of Consumer Finances, as interpreted and modeled by <a href="https://dqydj.com/net-worth-percentile-calculator/">tools like DQYDJ's Net Worth Percentile Calculator</a>.
It means you're ahead of 98% of American households in terms of total wealth—not income, not salary, but the full value of everything you own minus everything you owe.
But here's the thing: that number can vary, and quite a bit.
<h2 class="wp-block-heading">Why the Numbers Don't Always Match</h2>
Depending on who's doing the analysis, you'll find different definitions of what "top 2%" means. According to <a href="https://www.kiplinger.com/personal-finance/605075/are-you-rich">Kiplinger</a>, referencing data from <a href="https://thekickassentrepreneur.com/net-worth-percentile-calculator-usa/">The Kickass Entrepreneur</a>, the net worth needed to be in the top 2% is $2.7 million—less than half the Federal Reserve-based estimate.
Here's how that 2025 breakdown looks from Kiplinger's source:
<ul class="wp-block-list">
<li>Top 1%: $11.6 million </li>
<li>Top 2%: $2.7 million</li>
<li>Top 5%: $1.17 million </li>
<li>Top 10%: $970,000</li>
<li>Top 50%: $585,000</li>
</ul>
The discrepancy likely stems from a lack of clarity around source data. While Kiplinger's article presents precise thresholds, it doesn't cite original methodology or confirm whether the numbers are adjusted for inflation, household size, or asset categories. In contrast, most financial analysts and economists rely directly on Federal Reserve SCF data, which is released every three years and used as the national benchmark.
The point? Net worth rankings are estimates, not universal truths. But even with variation, the message is consistent: if you're aiming for the top 2%, you're reaching for a very exclusive bracket.
Trending: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
<h2 class="wp-block-heading">Where Top 2% Net Worth Typically Falls by Age</h2>
Net worth tends to grow over time, but simply aging into wealth isn't guaranteed. Based on percentile ranges <a href="https://www.federalreserve.gov/econres/scfindex.htm">interpreted from Federal Reserve data</a>, here's a rough idea of what top-tier net worth looks like across age groups:
<ul class="wp-block-list">
<li>Under 35: $1.2 million – $2 million</li>
<li>35–44: $2.5 million – $3.5 million</li>
<li>45–54: $4 million – $6 million</li>
<li>55–64: $6 million – $9 million</li>
<li>65+: $5 million – $8 million</li>
</ul>
By your 50s and 60s, hitting the top 2% becomes more common—but it usually requires a strong mix of market exposure, asset growth, and low liabilities.
<h2 class="wp-block-heading">What Really Counts Toward Net Worth?</h2>
Net worth includes everything you own—your home, cars, savings, retirement accounts, stocks, businesses, real estate, and more—minus your debts.
Top-tier households tend to own:
<ul class="wp-block-list">
<li>Brokerage investments outside retirement</li>
<li>Real estate beyond just a primary home</li>
<li>Business equity or private investments</li>
<li>Very little debt </li>
</ul>
In contrast, many households in the middle class have most of their net worth concentrated in home equity, which may grow in value but doesn't generate income—and isn't easily accessed.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">Does Household Size Matter?</h2>
Yes, but not in how thresholds are calculated. The top 2% figure is <a href="https://www.benzinga.com/25/05/45271981/are-you-richer-than-your-peers-heres-the-net-worth-it-takes-at-every-age-to-be-in-the-top-10">measured per household</a>, not per person. That means a single-income earner needs to work harder to get there than a dual-income couple with shared expenses and investments.
Household dynamics—whether you're single, partnered, a parent, or child-free—can shape how fast you accumulate wealth. But the ranking system doesn't adjust for that.
<h2 class="wp-block-heading">So… Are You Rich?</h2>
"Rich" is a subjective term. For some, it's about freedom. For others, it's about security. But if you're aiming to rank among the statistically wealthiest households, net worth is where the rubber meets the road.
Whether you lean on the higher $5.5 million estimate or the more conservative $2.7 million projection, the idea is the same: the top 2% isn't just about having money. It's about having <a href="https://www.benzinga.com/money/are-you-rich">sustained, diversified, low-liability wealth</a>.
You don't need to live like the ultra-rich to build toward this bracket—but if your assets are compounding, your debts are minimal, and your investments are doing the heavy lifting, you might be a lot richer than you think.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Personal Finance

How Rich Are You? This Is The Net Worth It Takes To Join The Top 2% Of Households

Stifel analyst Stephen Gengaro maintains Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Buy and lowers the price target from $12 to $10.

News

Price Target

Analyst Ratings

PTEN

Stifel Maintains Buy on Patterson-UTI Energy, Lowers Price Target to $10

RBC Capital analyst Jonathan Atkin maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Sector Perform and raises the price target from $265 to $270.

TMUS

RBC Capital Maintains Sector Perform on T-Mobile US, Raises Price Target to $270

UBS analyst Avinatan Jaroslawicz maintains EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy and raises the price target from $570 to $715.

UBS Maintains Buy on EMCOR Group, Raises Price Target to $715

Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) has outperformed the market over the past 20 years by 1.58% on an annualized basis producing an average annual return of 10.07%. Currently, Lowe's Companies has a market capitalization of $126.27 billion. 
Buying $1000 In LOW: If an investor had bought $1000 of LOW stock 20 years ago, it would be worth $6,816.22 today based on a price of $225.31 for LOW at the time of writing.
<h3>Lowe's Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753454716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Lowe's Companies 20 Years Ago Would Be Worth This Much Today

Stifel analyst Simon Yarmak maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Hold and lowers the price target from $51.25 to $49.25.

GLPI

Stifel Maintains Hold on Gaming and Leisure Props, Lowers Price Target to $49.25

WIIM

Healthpeak Properties shares are trading lower after the company reported worse-than-expected Q2 FFO and sales and affirmed FY25 FFO guidance below estimates.

RBC Capital analyst Keith Mackey maintains Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Outperform and lowers the price target from $9 to $8.5.

RBC Capital Maintains Outperform on Patterson-UTI Energy, Lowers Price Target to $8.5

Stifel analyst Ruben Roy maintains Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) with a Buy and raises the price target from $45 to $52.

FLEX

Stifel Maintains Buy on Flex, Raises Price Target to $52

Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $90 to $95.

Stifel Maintains Buy on Edwards Lifesciences, Raises Price Target to $95

Barclays analyst George Wang maintains Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) with a Overweight and raises the price target from $50 to $60.

Barclays Maintains Overweight on Flex, Raises Price Target to $60

RBC Capital analyst Steven Shemesh maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Outperform and raises the price target from $98 to $104.

ORLY

RBC Capital Maintains Outperform on O'Reilly Automotive, Raises Price Target to $104

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and raises the price target from $90 to $95.

Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95

Barclays analyst Julian Mitchell maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Equal-Weight and raises the price target from $185 to $193.

Barclays Maintains Equal-Weight on Dover, Raises Price Target to $193

RBC Capital analyst Ashish Sabadra maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $95 to $108.

NDAQ

RBC Capital Maintains Outperform on Nasdaq, Raises Price Target to $108

Stifel analyst Erik Rasmussen maintains Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) with a Buy and raises the price target from $190 to $205.

Stifel Maintains Buy on Digital Realty Trust, Raises Price Target to $205

Barclays analyst Adrienne Yih maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Overweight and raises the price target from $128 to $134.

DECK

Barclays Maintains Overweight on Deckers Outdoor, Raises Price Target to $134

Macro Notification

Politics

General

Reuters Cites EU Officials And Diplomats Saying European Framework Trade Deal With United States Could Happen This Weekend

RBC Capital analyst Ken Herbert maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Sector Perform and raises the price target from $265 to $280.

RBC Capital Maintains Sector Perform on L3Harris Technologies, Raises Price Target to $280

Barclays analyst Brandt Montour maintains Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Overweight and raises the price target from $127 to $131.

CHDN

Barclays Maintains Overweight on Churchill Downs, Raises Price Target to $131

Management

Press Releases

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Health Care

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Earnings

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Comments

Structure Therapeutics

Structure Therapeutics (GPCR) Opzioni

Structure Therapeutics (NASDAQ:GPCR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO